NC-KBI-BIOPHARMA
15.4.2024 14:01:35 CEST | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chief Business Officer, solidifying KBI’s Executive Team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415842099/en/
JB Agnus, Chief Business Officer, KBI Biopharma, Inc. (Photo: Business Wire)
JB brings more than two decades of experience across various sectors of the biopharmaceutical industry with expertise in commercial development in biologics, small molecule APIs, antibody-drug conjugates (ADCs), and the latest advancements in cell and gene therapies. With a proven track record of implementing winning sales strategies and cultivating high-performing teams, JB will lead KBI’s global business development initiatives, driving the company towards continued growth and sustained success. This pivotal role is focused on building and maintaining long-lasting partnerships with KBI’s current and future customers around the globe. JB’s commitment to fostering relationships with external partners and internal team members alike is a value that aligns well with KBI’s collaborative culture.
“Our dedication to growth and commitment to our partners, their patients, and our people guide every decision at KBI Biopharma,” remarked J.D. Mowery, President & CEO of KBI Biopharma. “JB’s appointment underscores this dedication, perfectly aligning with our team’s mission to deliver innovative, top-tier solutions tailored to our customers' evolving needs. His servant leadership philosophy will further fortify our team, propelling KBI to new heights.”
“KBI Biopharma is an innovator in the testing, development, manufacturing, and commercialization of life-changing therapies,” said JB Agnus, Chief Business Officer of KBI Biopharma. “Strong partnerships are at the core of KBI’s success. I am excited to join the passionate team at KBI, who are committed to ensuring transformative treatments reach those in need by nurturing meaningful customer relationships.”
Before joining KBI, JB held leadership roles in business development at AGC Biologics, Ajinomoto Bio-Pharma Services, Novasep, and Isochem. He holds a Master of Science in Chemical Engineering from Centrale Marseille.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, and microbial programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with six locations in Europe and the USA. More information is available at www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415842099/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Convera Appoints Industry Leader Meaghan Riley as Chief Commercial Officer to Scale Commercial Growth and Expand Revenue Opportunities29.1.2026 17:14:00 CET | Press release
Former Google Cloud and SAP executive will build on Convera’s success and leadership in the commercial payments sector Convera, a global leader in commercial payments, today announces the appointment of Meaghan Riley to Chief Commercial Officer, as the company continues its growth trajectory, expands to new markets, and drives scalable revenue opportunities across geographies and sectors. Prior to Convera, Meaghan was Chief Operating Officer for Google Cloud North America, where she led a major go-to-market transformation and launched high-growth segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129799440/en/ Meaghan Riley, Chief Commercial Officer, Convera “Meaghan’s impressive career journey and proven track record brings exceptional experience and unique assets that will strengthen our leadership team at this pivotal moment in Convera’s journey,” said Patrick Gauthier, CEO, Convera. “Meaghan’s leadership will be
New Year, New Solutions: AMRA Medical Continues Commitment to Innovation & Data-Driven Excellence29.1.2026 16:23:00 CET | Press release
AMRA Medical, the global leader in MRI-based fat distribution and muscle composition analytics, is excited to share our brand repositioning supported by the launch of a refreshed website and the introduction of a new tagline, “Insights Within.” This strategic update reflects AMRA’s commitment to placing clients and collaborators at the center of our vision: to be the most trusted, insights-driven imaging partner in the pursuit of preventing and curing disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129457626/en/ The new website provides a more structured and transparent presentation of AMRA’s biomarkers and research services, enabling our partners to have a clear understanding of our offerings, as well as the scientific value and applications of these solutions. For the first time, we’re introducing Imaging Biomarkers and Insights Biomarkers: clearly-defined, intentional offerings that are designed with your trial
NTT DATA Signs Strategic Collaboration Agreement with AWS to Accelerate Enterprise Cloud and Agentic AI Adoption29.1.2026 14:00:00 CET | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced a multi-year Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to help enterprises modernize legacy systems, adopt agentic AI responsibly and scale innovation across industries. Combining NTT DATA’s expertise in cloud transformation, cloud-native modernization and Agentic AI with the scale and innovation velocity of AWS services, the collaboration will deliver tailored enterprise solutions that modernize mission-critical workloads, build secure cloud foundations and drive measurable business outcomes across regulated and high-growth industries. Under the agreement, NTT DATA and AWS will accelerate enterprise transformation in four priority areas: AI-driven large-scale cloud transformation: Accelerating the migration and modernization of on-premises workloads on AWS, leveraging generative and agentic AI, automation and data platforms to unlock new business models and drive int
U.S. Department of Energy and Kyoto Fusioneering Launch Strategic Partnership to Build Critical Fusion Infrastructure and Accelerate Deployment of Commercial Fusion Power29.1.2026 14:00:00 CET | Press release
Today, the U.S. Department of Energy (DOE) and Kyoto Fusioneering (KF) established a landmark partnership to deliver critical fusion infrastructure and perform collaborative R&D to drive down technology and commercialization risk. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127164854/en/ Anchored by a new public-private partnership between KF and Oak Ridge National Laboratory (ORNL) that leverages each institution’s expertise in fusion technology to develop world-leading fusion test facilities and technology, this agreement establishes a new paradigm in U.S.-Japan allied cooperation and public-private partnership towards accelerating the deployment of commercial fusion power. Under the new partnership, KF and ORNL will commence joint research and development activities focused on fusion breeding blanket systems, a critical technology for producing the tritium fuel needed to sustain fusion power generation. This include
Esri Earns ISO Certification, Reinforcing Commitment to Data Security29.1.2026 14:00:00 CET | Press release
International Standard Ensures ArcGIS Readiness to Protect Information, Compliance Across Industries Esri, the global leader in location intelligence, has received ISO/IEC 27001:2022 certification. This certification enables Esri's ArcGIS users to meet data residency and local regulatory requirements and ensures that Esri’s security practices comply with the requirements set by the International Organization for Standardization (ISO). ISO/IEC 27001:2022 certification provides a globally recognized framework for establishing, implementing, maintaining, and continually improving an information security management system. Esri's certification demonstrates that its system preserves the confidentiality, integrity, and availability of the platforms, services, and applications used to process, transmit, and store customer assets. "As enterprises simultaneously navigate escalating cyber threats and complex data residency regulations, our certification provides critical assurance that we mainta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom